Effects of sevelamer treatment on cardiovascular abnormalities in mice with chronic renal failure

Kidney International

Volumn 84, Issue 3, 2013, Pages 491-500

  Maizel, Julien ^a,b   Six, Isabelle ^a   Dupont, Sebastien ^a   Secq, Edouard ^a   Dehedin, Benedicte ^a,b   Barreto, Fellype C ^a   Benchitrit, Joyce ^a   Poirot, Sabrina ^a   Slama, Michel ^a,b   Tribouilloy, Christophe ^a,b   Choukroun, Gabriel ^a,b   Mazière, Jean C ^a,b   Drueke, Tilman B ^a   Massy, Ziad A ^a,b  

^a UNIVERSITÉ DE PICARDIE JULES VERNE   (France)

^b AMIENS UNIVERSITY HOSPITAL   (France)

Author keywords

aortic stiffness; chronic renal failure; left ventricular hypertrophy; mouse; phosphate; sevelamer HC1

Indexed keywords

FIBROBLAST GROWTH FACTOR 23; PHOSPHATE; SEVELAMER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL STIFFNESS; ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; DIASTOLE; DIASTOLIC DYSFUNCTION; DRUG EFFECT; FEMALE; HEART LEFT VENTRICLE FILLING; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HYPERPHOSPHATEMIA; MULTIPLE REGRESSION; NONHUMAN; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PULSE WAVE; SHAM PROCEDURE; TREATMENT DURATION;

ANIMALS; CARDIOVASCULAR SYSTEM; CHELATING AGENTS; DIASTOLE; DISEASE MODELS, ANIMAL; FEMALE; HYPERTROPHY, LEFT VENTRICULAR; KIDNEY; KIDNEY FAILURE, CHRONIC; MICE; MICE, INBRED C57BL; PHOSPHATES; POLYAMINES; PULSE WAVE ANALYSIS; REGRESSION ANALYSIS; VASCULAR STIFFNESS;

EID: 84883464346     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2013.110     Document Type: Article

References (45)

1. Go AS, Chertow GM, Fan D et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305.
2. Onufrak SJ, Bellasi A, Shaw LJ et al. Phosphorus levels are associated with subclinical atherosclerosis in the general population. Atherosclerosis 2008; 199: 424-431.
3. Dhingra R, Sullivan LM, Fox CS et al. Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med 2007; 167: 879-885.
4. Giachelli CM. Vascular calcification: In vitro evidence for the role of inorganic phosphate. J Am Soc Nephrol 2003; 14: S300-S304.
5. Jono S, McKee MD, Murry CE et al. Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 2000; 87: E10-E17.
6. Ganesh SK, Stack AG, Levin NW et al. Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001; 12: 2131-2138.
7. Shuto E, Taketani Y, Tanaka R et al. Dietary phosphorus acutely impairs endothelial function. J Am Soc Nephrol 2009; 20: 1504-1512.
8. Kestenbaum B, Sampson JN, Rudser KD et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 2005; 16: 520-528.
9. Lau WL, Pai A, Moe SM et al. Direct effects of phosphate on vascular cell function. Adv Chronic Kidney Dis 2011; 18: 105-112.
10. Goodman WG, Goldin J, Kuizon BD et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000; 342: 1478-1483.
11. Goldberg DI, Dillon MA, Slatopolsky EA et al. Effect of renagel, a nonabsorbed, calcium- and aluminium-free phosphate binder, on serum phosphorus, calcium, and intact parathyroid hormone in end-stage renal disease patients. Nephrol Dial Transplant 1998; 13: 2303-2310.
12. Nikolov IG, Joki N, Maizel J et al. Pleiotropic effects of the non-calcium phosphate binder sevelamer. Kidney Int Suppl 2006; S16-S23.
13. Zoppellaro G, Faggin E, Puato M et al. Fibroblast growth factor 23 and the bone-vascular axis: Lessons learned from animal studies. Am J Kidney Dis 2012; 59: 135-144.
14. Faul C, Amaral AP, Oskouei B et al. FGF23 induces left ventricular hypertrophy. J Clin Invest 2011; 121: 4393-4408.
15. Shimada T, Hasegawa H, Yamazaki Y et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 2004; 19: 429-435.
16. Gutierrez O, Isakova T, Rhee E et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 2005; 16: 2205-2215.
17. Antoniucci DM, Yamashita T, Portale AA. Dietary phosphorus regulates serum fibroblast growth factor-23 concentrations in healthy men. J Clin Endocrinol Metab 2006; 91: 3144-3149.
18. Donate-Correa J, Mora-Fernández C, Martínez-Sanz R et al. Expression of FGF23/KLOTHO system in human vascular tissue. Int J Cardiol; e-pub ahead of print 24 September 2011.
19. Urakawa I, Yamazaki Y, Shimada T et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 2006; 444: 770-774.
20. Mirza MA, Larsson A, Lind L et al. Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community. Atherosclerosis 2009; 205: 385-390.
21. Nagano N, Miyata S, Abe M et al. Effect of manipulating serum phosphorus with phosphate binder on circulating PTH and FGF23 in renal failure rats. Kidney Int 2006; 69: 531-537.
22. Koiwa F, Kazama JJ, Tokumoto A et al. Sevelamer hydrochloride and calcium bicarbonate reduce serum fibroblast growth factor 23 levels in dialysis patients. Ther Apher Dial 2005; 9: 336-339.
23. Oliveira RB, Cancela AL, Graciolli FG et al. Early control of PTH and FGF23 in normophosphatemic CKD patients: A new target in CKD-MBD therapy? Clin J Am Soc Nephrol 2010; 5: 286-291.
24. Cancela AL, Oliveira RB, Graciolli FG et al. Fibroblast growth factor 23 in hemodialysis patients: Effects of phosphate binder, calcitriol and calcium concentration in the dialysate. Nephron Clin Pract 2011; 117: C74-c82.
25. Maizel J, Six I, Slama M et al. Mechanisms of aortic and cardiac dysfunction in uremic mice with aortic calcification. Circulation 2009; 119: 306-313.
26. Vanholder R, Massy Z, Argiles A et al. Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol Dial Transplant 2005; 20: 1048-1056.
27. Lekawanvijit S, Kompa AR, Wang BH et al. Cardiorenal syndrome: The emerging role of protein-bound uremic toxins. Circ Res 2012; 111: 1470-1483.
28. Block GA, Hulbert-Shearon TE, Levin NW et al. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis 1998; 31: 607-617.
29. Qunibi W, Moustafa M, Muenz LR et al. A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: The Calcium Acetate Renagel Evaluation-2 (CARE-2) study. Am J Kidney Dis 2008; 51: 952-965.
30. Block GA, Spiegel DM, Ehrlich J et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 2005; 68: 1815-1824.
31. Chertow GM, Burke SK, Raggi P. Treat to Goal Working Group. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002; 62: 245-252.
32. Raggi P, Bellasi A, Ferramosca E et al. Association of pulse wave velocity with vascular and valvular calcification in hemodialysis patients. Kidney Int 2007; 71: 802-807.
33. Jüppner H, Wolf M. aKlotho: FGF23 coreceptor and FGF23-regulating hormone. J Clin Invest 2012; 122: 4336-4339.
34. Caglar K, Yilmaz MI, Saglam M et al. Short-term treatment with sevelamer increases serum fetuin-a concentration and improves endothelial dysfunction in chronic kidney disease stage 4 patients. Clin J Am Soc Nephrol 2008; 3: 61-68.
35. Six I, Maizel J, Barreto FC et al. Effects of phosphate on vascular function under normal conditions and influence of the uraemic state. Cardiovasc Res 2012; 96: 130-139.
36. London GM. Left ventricular alterations and end-stage renal disease. Nephrol Dial Transplant 2002; 17(Suppl 1): 29-36.
37. Amann K, Tö rnig J, Kugel B et al. Hyperphosphatemia aggravates cardiac fibrosis and microvascular disease in experimental uremia. Kidney Int 2003; 63: 1296-1301.
38. Nakamura H, Tokumoto M, Mizobuchi M et al. Novel markers of left ventricular hypertrophy in uremia. Am J Nephrol 2010; 31: 292-302.
39. Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling-concepts and clinical implications: A consensus paper from an international forum on cardiac remodeling. Behalf of an international forum on cardiac remodeling. J Am Coll Cardiol 2000; 35: 569-582.
40. Li JM, Brooks G. Downregulation of cyclin-dependent kinase inhibitors p21 and p27 in pressure-overload hypertrophy. Am J Physiol 1997; 273: H1358-H1367.
41. Chue CD, Edwards NC, Moody WE et al. Serum phosphate is associated with left ventricular mass in patients with chronic kidney disease: A cardiac magnetic resonance study. Heart 2012; 98: 219-224.
42. Neves KR, Graciolli FG, dos Reis LM et al. Adverse effects of hyperphosphatemia on myocardial hypertrophy, renal function, and bone in rats with renal failure. Kidney Int 2004; 66: 2237-2244.
43. Gagnon RF, Ansari M. Development and progression of uremic changes in the mouse with surgically induced renal failure. Nephron 1990; 54: 70-76.
44. Sahn DJ, DeMaria A, Kisslo J et al. Recommendations regarding quantitation in m-mode echocardiography: Results of a survey of echocardiographic measurements. Circulation 1978; 58: 1072-1083.
45. Tei C, Nishimura RA, Seward JB et al. Noninvasive doppler-derived myocardial performance index: Correlation with simultaneous measurements of cardiac catheterization measurements. J Am Soc Echocardiogr 1997; 10: 169-178.